Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application

Galderma

Status and phase

Completed

Phase 4

Conditions

Dermatitis, Atopic

Treatments

Other: Emollient - Cetaphil Advanced

Study type

Interventional

Funder types

Industry

Identifiers

NCT01063218

BR.09.001

Details and patient eligibility

About

The main goal of this present study is evaluate the decreasing of necessity of topic corticoids usage to control outbreaks of light to moderate atopic dermatitis by using the correct emollients.

Enrollment

74 estimated patients

Sex

All

Ages

2 to 10 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male or Female patients
2 to 10 years old.
with light to moderate with no signs of acute/ sub-acute eczema or in activity.
Subjects can not present inflammatory lesions, erythema, edema, eschar, excoriation and lichens.
Subjects can present light to moderate dryness.

Exclusion criteria

Subjects presenting any serious systemic disease
Subjects with medical history regarding serious asthma
Subjects with known or suspected allergy to one of the investigational products
Subjects with acute atopic eczema or in activity, needing systemic antibiotics
Subjects with signs of active infections on skin
Subjects whose parents or legal guardian seem to have difficulty in understand the informed consent form (ICF)
Female subjects who are not in pre-menarche period.
Subjects who need topic corticoids or any other medication that can interfere on Atopic Dermatitis during the study.
Patient with a wash-out period for treatment less than:
injectable corticoids: 60 days
systemic corticoids: 15 days
topic corticoids: 8 days
topic immunomodulator: 8 days
antihistaminic : 48 hours